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that the GP had referred them to another doctor for evaluation
and treatment. Most women in the UK ﬁrst discussed UI with a
GP whereas in Germany most discussed UI with a specialist. In
Spain and France about half the women ﬁrst discussed their UI
with a GP. CONCLUSIONS: GPs are involved to varying degrees
in the initial management of UI in France, Germany, Spain 
and the UK. Even in countries where women have a choice of
whether to see a GP or specialist about UI many choose to have
their ﬁrst contact with a GP.
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SUMMARIZING POPULATION HEALTH USING EQ-5D
Chuang LH, Kind P
University of York,York, UK
OBJECTIVES: Summary measures of population health (SMPH)
are used by national governments and international agencies 
for comparative purposes. Such measures have other uses, for
example, in monitoring changes in health status over time. Com-
peting approaches for calculating SMPH have been developed
using different metrics: disability-adjusted life years (DALY) and
quality-adjusted life years (QALY). This lack of standardization
in approach might produce conﬂicting results. The present study
was designed to measure disease burden in a US national popu-
lation survey (MEPS) to test both approaches. METHODS: Two
methods are compared here: ﬁrst, the health expectancy method,
computing health-adjusted life expectancy by combining health
related quality of life (HrQoL) and survival data; second, the
health gap method, measuring disease burden by combining the
losses due to premature mortality and non-fatal conditions. Both
EQ-5D social preference weights and Global Burden of Disease
disability weights are employed to assess the effect of different
scoring systems. Four disease areas were studied: diabetes,
stroke, coronary heart disease (CHD) and asthma. RESULTS:
Using the health expectancy method based on EQ-5D values, the
highest QALY loss of 3.67 years per person was associated with
CHD, followed by diabetes (1.26), stroke (1.15) and asthma
(0.57). The results based on disability weights had the same rank
order among diseases but varied in magnitude by between 1%
and 42% compared to EQ-5D estimates. Results were similar
using the health gap method. Disability-weighted estimate for
CHD was 8508 thousand DALYs, followed by diabetes (4378),
stroke (3277) and asthma (1429); EQ-5D values produced the
same rank order but variation was lower (2% to 15% lower).
CONCLUSIONS: A single metric for measuring health status in
clinical and population studies would help improve knowledge
transfer between health care decision-makers. EQ-5D has poten-
tial value as a summary measure of population health.
INFECTION
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OBJECTIVES: Pneumococcal (Pnc) disease represents a major
health care concern being associated with severe complications.
Scope of this study was to evaluate the budgetary impact effect
of providing vaccination with seven-valent pneumococcal 
conjugate vaccine (PCV) to newborns in Lombardy (Italy).
METHODS: Budget impact analysis was applied to the 2004
cohort of newborns of Lombardy: efﬁcacy data as number of
pneumonia and acute otitis media (AOM) cases, and consump-
tion of resources were derived from a large multicenter single-
blind clinical study (results published) of vaccinated versus
unvaccinated Italian children. Vaccinated children were adminis-
tered 3 doses of PCV at 3, 5 and 11 months of age; Pnc morbid-
ity was recorded until the 30th month of age. Economic analysis
was performed in the perspective of the third party payer, con-
sidering direct costs (vaccine doses, administration costs, drugs,
visits and hospitalisations for management of Pnc disease com-
plications); unit cost of resources (2006 values) was retrieved from
national reimbursement tariff lists and other published sources.
RESULTS: The cost of vaccination was calculated as €133/
patient; cost of pneumonia and AOM were calculated as €2258
and €31 per case. Vaccination of the whole newborns population
of Lombardy would avoid about 6700 cases of AOM and 2700
cases of pneumonia. The economic effect of vaccination would
be a net saving, ranging from €million 1.0 to 0.8 and 0.5 for
respectively 100%, 80% and 50% vaccination coverage. These
savings may be underestimated when considering the economic
effects on cases of meningitis, the extension of vaccination bene-
ﬁts after the second year of age in the vaccinated infants and the
effect of herd immunity on total population. CONCLUSION:
Our analysis suggests that the use of PCV in infants is likely to
be economically justiﬁed due to savings from pneumonia and
AOM cases averted, in the population of newborns of Lombardy.
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OBJECTIVES: Indicators to measure the quality of health care
are increasingly being developed and used both by health care
professionals and policy makers. In the context of increasing
costs related to antimicrobial use and resistance we aimed to
develop valid antibiotic prescribing quality indicators for 
ambulatory care, producible on the basis of present ESAC
(www.ua.ac.be/ESAC) data on antibiotic utilisation.
METHODS: Experts from 15 countries participating in a Euro-
pean Science Foundation workshop in September 2005 proposed
a set of 24 indicators and subsequently scored these indicators
for their relevance to controlling antimicrobial resistance, patient
health beneﬁt, prescription cost-effectiveness and public health
policy making using a scale ranging from 1 (= completely dis-
agree), over 5 (= uncertain) to 9 (= completely agree). The scores
were processed according to the UCLA-RAND appropriateness
method and each indicator was judged valid if there was con-
sensus and the median score was not within the 1–6 interval.
RESULTS: Twenty-two participants scored. Nine indicators
were rated as valid antibiotic prescribing indicators on all four
dimensions and three extra for their relevance at least to pre-
scription cost-effectiveness. The 2004 indicator values of a valid
set of 12 quality indicators of cost-effective antibiotic utilsation
are available for 28 individual countries. The most informative
indicator “total outpatient use” varied more than threefold
between the countries with the highest (33.4 DDD per 1000
inhabitants per day (DID) in Greece) and lowest (9.2 DID in
Russia) use. CONCLUSIONS: In line with the main objectives
of antimicrobial use surveillance at the European level, this
subset can be used to describe antibiotic use in ambulatory care
in order to assess the quality of antibiotic prescribing and its
cost-effectiveness. The indicator values allow individual coun-
tries to position themselves and to deﬁne their own benchmark,
A206 Abstracts
based on the epidemiology of infectious diseases, national guide-
lines, and pricing and reimbursement mechanisms.
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OBJECTIVE: The nation’s largest single provider of health care
to those infected with Human Immunodeﬁciency Virus (HIV) is
the Department of Veterans Affairs (VA). The clinical effective-
ness of highly active antiretroviral therapy (HAART) depends
considerably on an individual’s ability to adhere closely to
therapy. The objective of this study was to assess the relation-
ship between patient adherence to HAART and the cost-
effectiveness of HAART in antiretroviral-naïve HIV-infected VA
patients. METHODS: The overall design of the study is a hybrid
between an observational study and a decision-analytic model.
Kaplan-Meier survival estimates, calculated from the VA’s labo-
ratory and clinical data, were used to model HIV-disease pro-
gression. Pharmacy-based adherence was calculated using reﬁll
percent adherence obtained from prescription records; individu-
als were categorized as adherent if adherence was equal to or
greater than 95%. Inpatient and outpatient costs were derived
from the VA Health Economics Resource Center estimates. Out-
patient prescription costs were obtained from the VA’s Pharmacy
Beneﬁts Management database. Markov Monte Carlo simula-
tions were conducted to project the cost-effectiveness of adher-
ence to HAART. Costs and quality-adjusted life-years (QALY)
were discounted at 3%. RESULTS: For the ﬁve-year Markov
Monte Carlo simulations, the overall costs of adherent behavior
were lower than those of non-adherent behavior. In addition, the
projected QALYs of adherent behavior were greater than those
of non-adherent behavior; therefore, the cost-effectiveness of
non-adherent behavior was dominated by adherent behavior. 
For the 20-year simulations, the cost-effectiveness of adherent
behavior, compared to non-adherent behavior, was less than
$15,000/QALY. CONCLUSIONS: Medication non-adherence in
chronic conditions is a recognized public health problem. The
association between medication adherence and improved health
outcomes is well documented and the results of this study
provide further evidence of this relationship. In this study, the
marginal costs and effects associated with adherent behavior,
compared to non-adherent behavior, are well below acceptable
willingness-to-pay thresholds.
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OBJECTIVES: SA is the major cause of bacteraemia and a major
cause of morbidity and mortality in haemodialysis (HD) patients.
The objective was to assess the health care costs associated with
SA bacteraemia requiring hospitalisation in HD patients in
Belgium. METHODS: Data on resource utilization associated
with SA bacteremia were retrospectively collected from hospital
ﬁles. Eligible patients were HD patients requiring hospitalization
due to SA in the years 2002–2005. Centres were selected based
on setting (urban-rural) and region (north-south). Direct medical
costs from the payers’ perspective were considered. Costs were
obtained by multiplying the intensity of medical resource con-
sumption in physical units by the direct cost per unit. RESULTS:
43 patients (32 males) were included with a mean age of 71.5
(St.Err 1.78). The majority of patients (55.8%) underwent dial-
ysis via central venous catheters, 44.2% via arteriovenous ﬁstu-
las. The pathogen was methicillin resistant SA (MRSA) in 49.1%
and methicillin sensitive SA (MSSA) in 58.1% of cases. Vascu-
lar access was the suspected source of bacteraemia in 62.8% of
patients. Bacteraemia related complications such as septic arthri-
tis or endocarditis, occurred in 41.9% of patients. Overall mor-
tality (within 90days) was 32.6%, SA bacteremia related
mortality was 23.3%. The mean total cost of SA bacteraemia
treatment was 8971€ (95%CI: 5082–12861). This includes hotel
cost (5945€), inhospital tests and procedures (716€), inpatient
and ambulatory drugs (497€), physician visits (34€) and bacter-
aemia related readmissions (1779€). MRSA patients showed
poorer outcomes, in terms of mortality as well as complications
and also incurred higher costs, 14,163€ versus 6188€ for MSSA
patients. In multivariate regression analysis on log-transformed
costs, signiﬁcant cost drivers were older age and the occurrence
of complications. Complications occurred more frequently in the
more costly MRSA patients. CONCLUSION: SA bacteraemia in
haemodialysis patients is associated with serious complications,
high mortality rates and high health care costs.
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OBJECTIVES: This cross-sectional, observational, case-control
study was undertaken in 4 EU countries and Canada to charac-
terize and quantify the humanistic and economic burden of
illness in AMD patients compared to elderly controls. Data for
Germany are reported herein. METHODS: Of 401 bilateral neo-
vascular AMD patients and 471 elderly non-AMD (control) sub-
jects, 83 AMD patients and 93 controls were recruited in
Germany. Physicians recorded demographic and treatment infor-
mation. Patients completed a telephone survey of the National
Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the
EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale
(HADS), and history of falls, fractures and health resource uti-
lization. The impact of AMD on functioning and health resource
utilization was compared between AMD patients and controls
using chi-square tests, analysis of variance, and multivariate
regression models. RESULTS: The adjusted mean (95% CI) NEI-
VFQ overall scale score was 51.31 (37.72, 64.90) in AMD
patients, which was substantially worse than in controls (96.31
[82.75, 109.87]) after adjusting for better-seeing eye visual
acuity, age, gender, and co-morbid diseases (p < 0.0001). AMD
patients reported signiﬁcantly more depression symptoms than
controls on the HADS scales (adjusted mean depression scores:
6.17 vs. 2.69, p < 0.0001) after adjusting for covariates. AMD
affected patients’ perceptions of their general health signiﬁcantly
more than control subjects measured by the EQ-5D (0.69 vs.
0.79, p = 0.0360). Average annual per patient costs were €12,156
